Access, Detection and Psychological Treatments
Launched by ONTARIO MENTAL HEALTH FOUNDATION · Nov 28, 2005
Trial Information
Current as of June 19, 2025
Unknown status
Keywords
ClinConnect Summary
Research Stream 1:
Treatment and Cost Effectiveness The primary aim of Stream 1 is to evaluate the effectiveness of a model-driven psychological intervention, CBT in preventing or delaying the onset of a psychotic illness and to evaluate the effectiveness of CBT in reducing presenting concerns in a sample of help-seeking individuals who have been operationally defined to be at ultra high risk of developing a psychotic illness. CBT will be compared to supportive therapy (ST). We will also examine the cost-effectiveness of a preventive approach. Using a cost-consequence approach, we will exa...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ages 12-30 years·
- • Meeting criteria for an "at risk mental state" based on one or more of the 3 Criteria of Prodromal Symptoms (COPS criteria) with severity as determined by ratings on the Scale of Prodromal Symptoms (SOPS) or the criteria for attenuated symptoms of the early prodromal state defined by the presence of at least two of 9 symptoms on the Bonn Scale for the Assessment of Basic Symptoms that have been demonstrated to have the best positive predictive value of developing schizophrenia (Klosterkötter et al., 2001). These criteria for the early prodromal state course are currently used in the multi-site European Prediction of Psychosis Study (EPOS) (Birchwood et al., 2002).
- Exclusion Criteria:
- • Meets criteria for current or lifetime axis I psychotic disorder.·
- • Meets DSM-IV criteria for an Axis 1 disorder where in the judgment of the evaluating clinician the diagnostic prodromal symptoms are clearly caused by the Axis 1 disorder. Note that, except for bipolar and psychotic disorders and a current major depression other DSM-IV disorders will not be exclusionary (e.g. substance abuse or dependence disorder, major depression, anxiety disorders, Axis II Disorders) as long as the disorder does not account for the diagnosis of prodromal symptoms.·
- • Use of substances where in the judgment of the evaluating clinician, the diagnostic prodromal symptoms are substance-induced.
- • Prior history of treatment with an antipsychotic for the current presenting symptoms or for any previous episode of psychotic symptoms.
- • Impaired intellectual functioning (IQ\< than 70).
- • Past or current history of a clinically significant central nervous system disorder which may confound or contribute to prodromal symptoms.
About Ontario Mental Health Foundation
The Ontario Mental Health Foundation is a leading organization dedicated to advancing mental health research and improving the quality of care for individuals with mental health challenges. By funding innovative clinical trials and fostering collaboration among researchers, healthcare providers, and community organizations, the Foundation aims to translate scientific discoveries into effective treatments and interventions. Committed to enhancing mental health outcomes across Ontario, the Foundation prioritizes evidence-based practices and promotes the integration of mental health services within the broader healthcare system. Through its initiatives, the Ontario Mental Health Foundation strives to empower individuals, reduce stigma, and contribute to a deeper understanding of mental health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Jean Addington, PhD
Principal Investigator
Centre for Addiction and Mental Health/ University of Toronto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials